AH-7921 Detection

Patent metadata

Field	Value
Publication number	US-10539557-B2
Application number	US-201615042095-A
Country	US
Kind code	B2
Filing date	Feb 11, 2016
Priority date	Feb 11, 2015
Publication date	Jan 21, 2020
Grant date	Jan 21, 2020

Abstract

Antibodies, immunoassay methods and kits for the detection and determination of 3,4-dichloro-N-[(1-(dimethylamino)cyclohexyl)methyl]benzamide and 3,4-dichloro-N-[(1-(methylamino)cyclohexyl)methyl]benzamide, as well as the precursory immunogens, are described.

First claim

What is claimed is:

1. A polyclonal antibody raised against an immunogen of the structure:

wherein the antibody binds to (i) 3,4-dichloro-N-[(1-(dimethylamino)cyclohexyl)methyl]benzamide and (ii) 3,4-dichloro-N-[(1-(methylamino)cyclohexyl)methyl]benzamide, and
wherein the antibody has a relative cross-reactivity of 100% to 3,4-dichloro-N-[(1-(dimethylamino)cyclohexyl)methyl]benzamide and 94.186% to 3,4-dichloro-N-[(1-(methylamino)cyclohexyl)methyl]benzamide, wherein the cross-reactivity is measured in the presence of a detecting agent comprising N-(carboxypropyl)-3,4-dichloro-N-[1-(methylamino)cyclohexyl)methyl]benzamide conjugated to horseradish peroxidase.

2. The polyclonal antibody according to claim 1 , which has been purified by immunoglobulin precipitation, antigen-specific affinity purification, size-exclusion chromatography or ion exchange chromatography.

3. The polyclonal antibody according to claim 1 , wherein the antibody is adsorbed on or attached to a solid state device.

4. A method of detecting or determining 3,4-dichloro-N-[(1-(dimethylamino)cyclohexyl)methyl]benzamide or 3,4-dichloro-N-[(1-(methylamino)cyclohexyl)methyl]benzamide in a sample comprising:
i) contacting the sample with a detecting agent and the polyclonal antibody according to claim 1 ; and
ii) detecting or determining the amount of the detecting agent bound to the polyclonal antibody.

5. The method according to claim 4 , wherein the polyclonal antibody is adsorbed on or attached to a solid state device.

6. The method according to claim 4 , wherein the detecting agent is conjugated to a labelling agent, and wherein the labelling agent is horseradish peroxidase (HRP).

7. The method according to claim 6 , wherein the presence of the labelling agent is detected or determined by a colour change in response to reaction of the labelling agent with a substrate.

8. The method according to claim 7 , wherein the colour change is detected or determined by reading the absorbance at 450 nm.

9. The method according to claim 4 , wherein the presence of the detecting agent linked to the polyclonal antibody can be detected or determined in between about 2 hours and about 10 minutes.

10. A kit comprising the polyclonal antibody according to claim 1 .

11. The kit according to claim 10 , in which the polyclonal antibody is adsorbed on or attached to a solid state device.

Assignees

• Randox Laboratories Ltd

Inventors

• Benchikh Elouard
• Mcconnell Ivan
• Fitzgerald Peter
• Lowry Philip

Classifications

• G01N33/9486

  Analgesics, e.g. opiates, aspirine · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C07K16/44 Primary

  against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids} · CPC title

• G01N33/5308 Primary

  for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites · CPC title